Clinical Trial Update: Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3) [Phase 3]

View source ↗

Summary

A Phase 3 trial in Chinese adults who are overweight or obese evaluating once-daily oral semaglutide (OASIS 3) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Overweight

Drugs mentioned

• Rybelsus (semaglutide)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Overweight, Obesity | Phase 3 | Status: COMPLETED